Tyruko ® (natalizumab-sztn), a biosimilar to Tysabri ® (natalizumab), has been made available by Sandoz, according to developer Polpharma Biologics.

The indication was restricted to only patients with DMD who are 4 years of age and older with a confirmed mutation in the DMD gene; the indication for non-ambulatory patients with DMD was removed.

Immigration experts warn the policy could make it easier for officers to deny visas based on their own judgment.

The sNDA was supported by data from a 4 week MUSE study and a long-term open-label study in children aged 2 to 5 years.

Findings showed both zanidatamab treatment arms demonstrated statistically significant and clinically meaningful improvements in PFS vs the SOC arm.

The allergy develops after a bite from the Lone Star tick, which can make the body react to alpha-gal, a sugar found in beef, pork, lamb and other mammalian meats. Many people experience hives, nausea ...

Nonopioids are noninferior on days 2 and 3 and during the postoperative period; higher patient satisfaction reported with nonopioids.

HealthDay News — Commonly used noncancer medications, including proton pump inhibitors, are associated with poorer survival and adverse events for patients with breast cancer, according to a study ...

Poherdy can be dispensed as a substitute for Perjeta without requiring a prescription change from a health care provider.

The outpatient procedure provides noninvasive magnetic stimulation through a cushioned helmet to induce electrical currents in localized regions of the prefrontal cortex.

The phase 3 Librexia ACS trial evaluating the safety and efficacy of milvexian after a recent acute coronary syndrome has been discontinued.

Rates higher among those aged 18 to 21 years, and more than nine in 10 users found the advice somewhat or very helpful.